S&P 500
$5,802.82
-0.7%
-$39.19
DJI
$41,603.07
-0.6%
-$256.02
NASDAQ
$18,737.21
-1.0%
-$188.53
Bitcoin
108,765.00
+0.2%
+256.00
AAPL
$195.55
-2.9%
-$5.81
AMZN
$201.33
-0.9%
-$1.77
GOOG
$169.68
-1.3%
-$2.30
META
$627.70
-1.4%
-$8.87
MSFT
$451.11
-0.8%
-$3.75
NVDA
$131.48
-1.0%
-$1.36
TSLA
$339.93
-0.3%
-$1.11
SpringWorks Therapeutics (NASDAQ: SWTX)
$46.46
(0.4%)
$0.20
Price as of May 23, 2025, 3:58 p.m. ET
SpringWorks Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
SpringWorks Therapeutics Company Info
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
News & Analysis
Featured Article
What Company Will Eli Lilly Buy Next?
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
David Haen | Jan 23, 2020
Featured Article
Here's Why SpringWorks Therapeutics Climbed 69% in December
The stock climbed after investors saw encouraging signs from a similar program.
Cory Renauer | Jan 12, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.